Galenicum Reaches €186 Million in 2022, 24% More than in 2021

Galenicum obtains revenues of €166 million in 2022, 24% more than the previous year. The Spanish company’s revenues, despite the increase in figures, was below what was originally estimated, €200 million.

If you want to find more details about Galenicum and read the latest financial news of the day, download for free our companion app, Born2Invest.

Galenicum, which includes Peninsula Capital as a minority shareholder, opened a new headquarters in Esplugues de Llobregat (Barcelona)

Pergamon has been the name given to this new plant that has an area of ​​4,000 square meters and has Research and Development (R&D) areas. In total, the company has invested €35 million in this plant.

The company is also preparing a generic drug for glyptic, an oral diabetes drug. This tablet was made in 2014, but its launch has not been possible in previous years due to the expiration of patents. Galenicum points out that his patent was validated in all European countries, but was challenged by direct competitors at the European Patent Office (EPO). Finally, the Catalan company passed the trial in October last year.  

Galenicum has invested €35 million in its new Esplugues factory in Llobregat

In addition, the Catalan company had income in the production area at its factory in Guadalix (Madrid). The factory produced 45% more medicines, almost 70 million boxes, among which the mass production of paracetamol stands out. The Madrid plant is also preparing to manufacture more complex drugs and manage the launch of multi-formats simultaneously, according to internal company sources.

Galenicum Axium, a subsidiary that focuses on the development of licenses and distribution of medicines for other companies and is one of the company’s main sources of income, had a turnover of €127 million in 2022, 41% more. Its second subsidiary Galenicum SAG, in charge of manufacturing pharmaceuticals, obtained €71 million compared to the previous year.

The Catalan company is also dedicated to the sale of bioequivalent medicines under its Vitae brand and also has a division specializing in dermatology. Both divisions had revenues of €25 million and €10 million, respectively.

In addition to the headquarters in Esplugues and the factory in San Agustín de Guadalix, the company has an international presence. In this sense, it has subsidiaries in Colombia, Ecuador, Peru, Chile, and India. It also has a commercial office in Mexico and is preparing an opening in the United Arab Emirates. In total, Galenicum sells in more than 50 countries and exports 48% of its production.

__

(Featured image by AlphaTradeZone via Pexels)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.